USES AND ABUSES OF ANALYSIS OF COVARIANCE IN CLINICAL-TRIALS
USES AND ABUSES OF ANALYSIS OF COVARIANCE IN CLINICAL-TRIALS
复制标题
DOI：
10.1016/0197-2456(85)90093-5
复制
发表时间：
1985-01-01
期刊：
影响因子：
--
通讯作者：
WILLIAMS, HJ
中科院分区：
文献类型：
--
作者：
EGGER, MJ;COLEMAN, ML;WILLIAMS, HJ
慢性病临床试验中的改善测量通常通过对原始增益或百分比变化进行t检验或方差分析（ANOVA）来比较基线数据与终点值。这种方法可能会产生误导，应考虑使用协方差分析（ANCOVA）。在临床试验中，正确使用ANCOVA可提高统计能力。它优于t检验的优势可能会因患者数量少、违反假设和技术应用不当而无效。ANCOVA在慢性疾病研究中的评价，与它的优点和缺点的例子，在风湿性疾病的几个药物试验中看到。建议其使用和决策树的非统计学家。
Measurement of improvement in clinical trials in chronic diseases commonly compares baseline data to endpoint values by performing t-tests or analysis of variance (ANOVA) on raw gains or percentage changes. This procedure can be misleading and the use of an analysis of covariance (ANCOVA) should be considered. Properly used, ANCOVA increased stastistical power in a clinical trial. Its advantage over t-tests can be nullified by small numbers of patients, violations of assumptions and incorrect application of the techniques. An evaluation of ANCOVA in chronic disease studies is given, with examples of its strengths and weaknesses as seen in several drug trials in the rheumatic diseases. Recommendations on its use and a decision tree for the nonstatistician are provided.